anti-CD37 DOTA CAR T-cell therapy (Nordic Nanovector)

N/A

Report date: 2025/03/14 16:41:35

Base Information

Drug Nameanti-CD37 DOTA CAR T-cell therapy (Nordic Nanovector)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionLeukocyte antigen CD37 modulators

TargetsLeukocyte antigen CD37

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNorway

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNordic Nanovector Asa

China Registration ClassN/A

Develop Information

Active CompaniesNordic Nanovector Asa

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A